RedHill Biopharma - Rapid progress with COVID-19 programme
RedHill’s global Phase II/III programme with opaganib against COVID-19 is progressing rapidly. An ongoing Phase IIa study in the US should complete...
212 Views
RedHill Biopharma - Movantik acquisition completed; sales booked
RedHill is now promoting Aemcolo for travellers’ diarrhoea (since December 2019), Talicia for H. pylori eradication (since March 2020) and the most...
326 Views
RedHill Biopharma - COVID-19 challenges and opportunities
The ongoing COVID-19 pandemic is causing unprecedented challenges for most companies. According to the latest business update (25 March), the...
234 Views
RedHill Biopharma - Transforming into a commercial pharma company
With two specialty GI products launched and a third one, Movantik, about to be acquired from AstraZeneca, RedHill is transforming into a fully...
590 Views
RedHill Biopharma - 2020 set to be a commercially transformative year
On 22 November 2019, RedHill held an investor and analyst day in New York with the focus on the two new products about to be launched in the US....
1.3k Views